OBJECTIVE: Copy number variants including microdeletion syndromes are poorly detected through traditional screening. While they can be diagnosed with invasive testing with chromosomal microarray analysis, cell-free DNA (cf DNA) screening is also currently available for detection of select microdeletions. Our study aims to investigate the costs and outcomes associated with detection of five microdeletion syndromes, using cf DNA to screen for microdeletions and aneuploidy compared to cf DNA for aneuploidy alone but in conjunction with ultrasound. STUDY DESIGN: A decision-analytic model was constructed using TreeAge software to compare cf DNA with microdeletions versus cf DNA with aneuploidies plus ultrasound in a theoretical cohort of 4,000,000 pregnancies for detection of 22q11.2, Prader-Willi, Angelman, Cri-du-chat, and 1p36 deletion syndromes. All probabilities, costs, and utilities were derived from literature. The primary outcome was incremental cost per quality-adjusted life year (QALY) in addition to terminations and procedure-related losses. Because the microdeletion results are available on all cf DNA testing, we set the incremental cost of cf DNA microdeletion screening to zero at baseline, but varied the cost in sensitivity analysis. RESULTS: Screening with cf DNA for microdeletions among all pregnant women would result in 75 fewer anomalous neonates as compared to cf DNA with ultrasound (Table) . This reduction is due to increased termination rates of fetuses with microdeletions in this group. Routine use of cf DNA with microdeletions resulted in more procedure-related losses and losses of normal fetuses. cf DNA with microdeletions would improve effectiveness by 752 QALYs and decrease cost by $83,524,493. When we varied the specificity of the screening test, we found that it remained cost-effective down to a specificity of 92%. With a threshold of $100,000/QALY, microdeletion screening is cost-effective up until an incremental cost over cf DNA for aneuploidy alone of $39.60 ( Figure) . CONCLUSION: For fetal detection of subchromosomal abnormalities in pregnancy, cf DNA with microdeletions is a cost-effective strategy compared to cf DNA for aneuploidies and ultrasound. The test characteristics of cf DNA with microdeletions require greater examination and study before being routinely recommended. OBJECTIVE: Cystic fibrosis is one of the most common autosomal recessive conditions. Medical-society guidelines recommend routine carrier screening for cystic fibrosis via targeted genotyping of 23 frequent single-nucleotide variants (SNVs) and short insertions or deletions (indels) in the CFTR gene. Screening for copynumber variants (CNVs) is recommended only when a reproductive partner is a known carrier. Here we assess the performance and clinical impact of routinely screening for SNVs, indels, and CNVs in a next-generation sequencing (NGS)-based expanded carrier screen (ECS). STUDY DESIGN: Pathogenic variants in CFTR from 103,718 patients were discovered via a validated NGS-based ECS. A custom algorithm identified CNVs via relative deviations in NGS read depth. Approximate CNV breakpoints were inferred from the NGS-depth profile. Positive CNVs were orthogonally assessed via multiplex ligation-dependent probe amplification (MLPA). CFTR CNV sensitivity was explored across a range of length scales via in silico simulations. RESULTS: Among carriers of cystic fibrosis, 98.7% had pathogenic SNVs or indels in the CFTR gene (79% had one of the 23 common variants), and the remaining 1.3% harbored a pathogenic CNV spanning at least one exon. In total, we observed 25 unique CNVs with a diversity of breakpoints, suggesting that algorithms must be configured to detect novel CNVs. Further, single-exon deletions were observed for seven different CFTR exons; analysis of confidence scores for these empirical deletions-coupled with extensive simulations-demonstrated that the bioinformatics pipeline was both accurate and robust, even for short CNVs. All CNVs identified via NGS were confirmed via MLPA. CONCLUSION: CNV detection maximizes identification of cystic fibrosis carriers and can be applied to all patients undergoing an NGS-based ECS test validated to detect these complicated variants. Clinical guidelines recommending screening of only the 23 most frequent variants miss critical identification of carriers and should be revisited.
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